HELICOBACTER PYLORI

Aihara, 1997, Mechanisms involved in Helicobacter pylori–induced interleukin-8 production by a gastric cancer cell line, MKN45, Infect Immun, 65, 3218, 10.1128/IAI.65.8.3218-3224.1997 Al-Assi, 1999, Noninvasive evaluation of Helicobacter pylori therapy: Role of fasting or postprandial gastrin, pepsinogen I, pepsinogen II, or serum IgG antibodies, Am J Gastroenterol, 94, 2367, 10.1111/j.1572-0241.1999.01359.x Allescher, 1995, Effect of human gastrin-17 with and without acid suppression on human esophageal motility, Z Gastroenterol, 33, 385 Anand, 1999, Ulcer and gastritis, Endoscopy, 31, 215, 10.1055/s-1999-13672 Bardhan, 1998, H. pylori (Hp) eradication with omeprazole (O), metronidazole (M) and amoxicillin (A): The impact of drug dosing and resistance on efficacy—the Homer story [abstract], Gastroenterology, 114, A65, 10.1016/S0016-5085(98)80264-3 Bazzoli, 1999, My approach to Helicobacter pylori eradication, Eur J Gastroenterol Hepatol, 11, S37 Blaser, 1997, Not all Helicobacter pylori strains are created equal: Should all be eliminated?, Lancet, 349, 1020, 10.1016/S0140-6736(96)09133-7 Blaser, 1999, Hypothesis: The changing relationships of Helicobacter pylori and humans: Implications for health and disease, J Infect Dis, 179, 1523, 10.1086/314785 Blaser, 1999, In a world of black and white, Helicobacter pylori is gray, Ann Intern Med, 130, 695, 10.7326/0003-4819-130-8-199904200-00019 Breuer, 1999, Costs of diagnosis and treatment of Helicobacter pylori infection: When does choosing the treatment regimen based on susceptibility testing become cost effective?, Am J Gastroenterol, 94, 725, 10.1111/j.1572-0241.1999.00943.x Broutet, 1998, Cag negative status: A risk factor for failure of Helicobacter pylori triple therapies in non-ulcer dyspepsia [abstract], Gut, 43, A79 Catalano, 1999, Comparative treatment of Helicobacter pylori-positive duodenal ulcer using pantoprazole at low and high doses versus omeprazole in triple therapy, Helicobacter, 4, 178, 10.1046/j.1523-5378.1999.99274.x Censini, 1996, cag, a pathogenicity island of Helicobacter pylori, encodes type I-specific and disease-associated virulence factors, Proc Natl Acad Sci U S A, 93, 14648, 10.1073/pnas.93.25.14648 Covacci, 1999, Helicobacter pylori virulence and genetic geography, Science, 284, 1328, 10.1126/science.284.5418.1328 Dammann, 1998, 7 vs 14 day treatment with pantoprazole, clarithromycin and metronidazole for cure of H. pylori infection in duodenal ulcer patients [abstract], Gut, 41, A95 Drewitz, 1997, The incidence of adenocarcinoma in Barrett's esophagus: A prospective study of 170 patients followed 4.8 years, Am J Gastroenterol, 92, 212 El-Omar, 1997, Helicobacter pylori infection and chronic gastric acid hyposecretion, Gastroenterology, 113, 15, 10.1016/S0016-5085(97)70075-1 El-Serag, 1998, Opposing time trends of peptic ulcer and reflux disease, Gut, 43, 327, 10.1136/gut.43.3.327 El-Serag, 1999, Ethnic variations in the occurrence of gastroesophageal cancers, J Clin Gastroenterol, 28, 135, 10.1097/00004836-199903000-00010 El-Serag, 1999, Corpus gastritis is protective against reflux oesophagitis, Gut, 45, 181, 10.1136/gut.45.2.181 Faber, 1927, Chronic gastritis: Its relation to achylia and ulcer, Lancet, 2, 902 Genta, 1994, The gastric cardia in Helicobacter pylori infection, Hum Pathol, 25, 915, 10.1016/0046-8177(94)90011-6 Go, 1994, How does Helicobacter pylori cause duodenal ulcer disease: The bug, the host, or both, J Gastroenterol Hepatol, 9, S8, 10.1111/j.1440-1746.1994.tb01294.x Graham, 1994, Benefits from elimination of Helicobacter pylori infection include major reduction in the incidence of peptic ulcer disease, gastric cancer, and primary gastric lymphoma, Prev Med, 23, 712, 10.1006/pmed.1994.1121 Graham, 1997, Can therapy ever be denied for Helicobacter pylori infection?, Gastroenterology, 113, S113, 10.1016/S0016-5085(97)80023-6 Graham, 1997, Helicobacter pylori infection in the pathogenesis of duodenal ulcer and gastric cancer: A model, Gastroenterology, 113, 1983, 10.1016/S0016-5085(97)70019-2 Graham, 2000, Therapy of Helicobacter pylori: Current status and issues, Gastroenterology, 118, 52, 10.1016/S0016-5085(00)70003-5 Graham, 1996, Helicobacter pylori does not migrate from the antrum to the corpus in response to omeprazole, Am J Gastroenterol, 91, 2120 Graham, 1999, Practical advice on eradicating Helicobacter pylori infection, Postgrad Med, 105, 137, 10.3810/pgm.1999.03.595 Gutierrez, 1997, Cure of Helicobacter pylori infection improves gastric acid secretion in patients with corpus gastritis, Scand J Gastroenterol, 32, 664, 10.3109/00365529708996515 Haruma, 1999, Eradication of Helicobacter pylori increases gastric acidity in patients with atrophic gastritis of the corpus—evaluation of 24-h pH monitoring, Aliment Pharmacol Ther, 13, 155, 10.1046/j.1365-2036.1999.00459.x Hirota, 1999, Specialized intestinal metaplasia, dysplasia, and cancer of the esophagus and esophagogastric junction: Prevalence and clinical data, Gastroenterology, 116, 277, 10.1016/S0016-5085(99)70123-X Holtmann, 1999, Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole, Gastroenterology, 117, 11, 10.1016/S0016-5085(99)70544-5 Houben, 1999, Efficacy of PPI-triple therapy in H. pylori (HP) positive patients with peptic ulcer versus patients with functional dyspepsia [abstract], Gastroenterology, 116, A190 Huang, 1999, The importance of clarithromycin dose in the management of Helicobacter pylori infection: A meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole, Aliment Pharmacol Ther, 13, 719, 10.1046/j.1365-2036.1999.00530.x Katicic, 1998, Eradication of H. pylori with two triple-therapy regimens of 7, 10 and 14 days duration [abstract], Gut, 41, A100 Khoury, 1999, Post-prandial ranitidine is superior to post-prandial omeprazole in control of gastric acidity in healthy volunteers, Aliment Pharmacol Ther, 13, 1211, 10.1046/j.1365-2036.1999.00587.x Khoury, 1999, Bedtime ranitidine does not eliminate the need for a second daily dose of omeprazole to suppress nocturnal gastric pH, Aliment Pharmacol Ther, 13, 675, 10.1046/j.1365-2036.1999.00499.x Klinkenberg-Knol, 1994, Long-term treatment with omeprazole for refractory reflux esophagitis: Efficacy and safety, Ann Intern Med, 121, 161, 10.7326/0003-4819-121-3-199408010-00001 Kuipers, 1996, Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication, N Engl J Med, 334, 1018, 10.1056/NEJM199604183341603 Kung, 1999, One-week ranitidine bismuth citrate versus colloidal bismuth subcitrate–based anti-Helicobacter triple therapy: A prospective randomized controlled trial, Am J Gastroenterol, 94, 721, 10.1111/j.1572-0241.1999.00942.x Labenz, 1997, Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis, Gastroenterology, 112, 1442, 10.1016/S0016-5085(97)70024-6 Labenz, 1997, Helicobacter pylori in gastro-oesophageal reflux disease: Causal agent, independent or protective factor?, Gut, 41, 277, 10.1136/gut.41.3.277 Labenz, 1996, Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer, Gastroenterology, 110, 725, 10.1053/gast.1996.v110.pm8608881 Labenz, 1997, Effect of curing Helicobacter pylori infection on intragastric acidity during treatment with ranitidine in patients with duodenal ulcer, Gut, 41, 33, 10.1136/gut.41.1.33 Lamberts, 1993, Long-term omeprazole therapy in peptic ulcer disease: Gastrin, endocrine cell growth, and gastritis, Gastroenterology, 104, 1356, 10.1016/0016-5085(93)90344-C Lamouliatte, 1998, Lansoprazole (Lanso) 30 mg or 60 mg combined with two antibiotics [amoxicillin (Amox) and clarithromycin (Clari) to eradicate Helicobacter pylori (H. pylori) [abstr], Gastroenterology, 114, A194, 10.1016/S0016-5085(98)80791-9 Lopez-Brea, 1999, Metronidazole resistance and virulence factors in Helicobacter pylori as markers for treatment failure in a paediatric population, FEMS Immunol Med Microbiol, 24, 183, 10.1016/S0928-8244(99)00024-3 Meining, 1997, H2-receptor antagonists and antacids have an aggravating effect on Helicobacter pylori gastritis in duodenal ulcer patients, Aliment Pharmacol Ther, 11, 729, 10.1046/j.1365-2036.1997.00196.x Meining, 1998, Changes in Helicobacter pylori–induced gastritis in the antrum and corpus during and after 12 months of treatment with ranitidine and lansoprazole in patients with duodenal ulcer disease, Aliment Pharmacol Ther, 12, 735, 10.1046/j.1365-2036.1998.00370.x Miehlke, 1997, Antimicrobial therapy of peptic ulcer, Int J Antimicrob Agents, 8, 171, 10.1016/S0924-8579(97)00368-3 O'Connor, 1999, Review article: Helicobacter pylori and gastro-oesophageal reflux disease—clinical implications and management, Aliment Pharmacol Ther, 13, 117, 10.1046/j.1365-2036.1999.00460.x Peghini, 1998, Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: A controlled study in normal subjects, Gastroenterology, 115, 1335, 10.1016/S0016-5085(98)70010-1 Perez-Perez, 1997, Country-specific constancy by age in CagA+ proportion of Helicobacter pylori infections, Int J Cancer, 72, 453, 10.1002/(SICI)1097-0215(19970729)72:3<453::AID-IJC13>3.0.CO;2-D Schultze, 1995, Helicobacter pylori reinfection with identical organisms: Transmission by the patients' spouses, Gut, 36, 831, 10.1136/gut.36.6.831 Segura, 1997, Furazolidone, amoxycillin, bismuth triple therapy for Helicobacter pylori infection, Aliment Pharmacol Ther, 11, 529, 10.1046/j.1365-2036.1997.00172.x Stolte, 1990, Elimination of Helicobacter pylori under treatment with omeprazole, Z Gastroenterol, 28, 271 Sung, 1999, One-week ranitidine bismuth citrate in combinations with metronidazole, amoxycillin and clarithromycin in the treatment of Helicobacter pylori infection: The RBC-MACH study, Aliment Pharmacol Ther, 13, 1079, 10.1046/j.1365-2036.1999.00580.x Verdu, 1995, Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole, Gut, 36, 539, 10.1136/gut.36.4.539 Verdu, 1996, Intragastric pH during treatment with omeprazole: Role of Helicobacter pylori and H. pylori–associated gastritis, Scand J Gastroenterol, 31, 1151, 10.3109/00365529609036903 Verdu, 1998, High concentrations of ammonia, but not volatile amines, in gastric juice of subjects with Helicobacter pylori infection, Helicobacter, 3, 97, 10.1046/j.1523-5378.1998.08068.x Vicari, 1997, Helicobacter pylori and acid peptic disorders of the esophagus: Is it conceivable?, Am J Gastroenterol, 92, 1097 Voutilainen, 1999, Complete and incomplete intestinal metaplasia at the oesophagogastric junction: Prevalences and associations with endoscopic erosive oesophagitis and gastritis, Gut, 45, 644, 10.1136/gut.45.5.644 Voutilainen, 1999, Specialized columnar epithelium of the esophagogastric junction: Prevalence and associations. The Central Finland Endoscopy Study Group, Am J Gastroenterol, 94, 913, 10.1111/j.1572-0241.1999.986_i.x Voutilainen, 1999, Chronic inflammation at the gastroesophageal junction (carditis) appears to be a specific finding related to Helicobacter pylori infection and gastroesophageal reflux disease. The Central Finland Endoscopy Study Group, Am J Gastroenterol, 94, 3175, 10.1111/j.1572-0241.1999.01513.x Werdmuller, 1997, Helicobacter pylori infection has no role in the pathogenesis of reflux esophagitis, Dig Dis Sci, 42, 103, 10.1023/A:1018841222856 Yamaoka, 1999, Relationship between Helicobacter pylori iceA, cagA, and vacA status and clinical outcome: Studies in four different countries, J Clin Microbiol, 37, 2274, 10.1128/JCM.37.7.2274-2279.1999 Yamaoka, 1998, Relationship of vacA genotypes of Helicobacter pylori to cagA status, cytotoxin production, and clinical outcome, Helicobacter, 3, 241, 10.1046/j.1523-5378.1998.08056.x